Natural Compound Attacks HER2 Positive Breast Cancer Cells (DukeHealth.org)
Feb. 17, 2014
A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.
Thomas and Janet Kean, Nick Valvano to Receive Duke’s Shingleton Award (DukeHealth.org)
Sept. 26, 2013
The Duke Cancer Institute has named Thomas and Janet Kean of Norwood, N.C., and Nick Valvano of Cary, N.C., president emeritus of The V Foundation for Cancer Research, as the 2013 recipients of the Shingleton Award. The award recognizes the outstanding service and generosity of individuals who are committed to the war against cancer.
Doctors should discuss financial concerns of cancer patients (DukeHealth.org)
May 16, 2013
Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
Duke researchers describe how breast cancer cells acquire drug resistance (DukeHealth.org)
May 7, 2013
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute.